Efficacy of Curcumin as Adjuvant Therapy to Induce or Maintain Remission in Ulcerative Colitis Patients: an Evidence-based Clinical Review

Authors

  • Marcellus Simadibrata Department of Internal Medicine, Faculty of Medicine Universitas Indonesia – Cipto Mangunkusumo Hospital, Jakarta, Indonesia
  • Christopher Christian Halimkesuma Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia
  • Benedicta Mutiara Suwita Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia

Keywords:

curcumin, remission, maintenance, ulcerative colitis

Abstract

Background: treatment guidelines for ulcerative colitis (UC) not yet established. Currently, mesalazine, corticosteroids, and immunomodulators are treatment options for UC. However, they are known to have unpleaseant side effects such as nausea, vomiting, headaches, hepatitis, and male infertility. Curcumin is found in Turmeric plants (Curcuma longa L.), which possesses both anti-inflammatory and antioxidant properties. This study aimed to determine whether curcumin as adjuvant therapy can induce or maintain remission in UC patients. Methods: structured search in three database (Cochrane, PubMed, Proquest) using “Curcumin”, “remission” and “Ulcerative Colitis” as keywords. Inclusion criteria is randomized controlled trials (RCTs), meta-analysis, or systematic review using curcumin as adjuvant therapy in adult UC patients.Results: we found 49 articles. After exclusion, three RCTs were reviewed; two examined curcumin efficacy to induce remission and one for remision maintenance in UC. Curcumin was significantly more effective than placebo in all RCTs. The efficacy of curcumin could be explained by its anti-inflammatory properties, which inhibit NF-kB pathway. Regulation of oxidant/anti-oxidant balance can modify the release of cytokines. However, methods varied between RCTs. Therefore, they cannot be compared objectively. Futhermore, the sample size were small (n= 50, 45, 89) therefore the statistical power was not enough to generate representative results in all UC patients.Conclusion: Available evidence showed that curcumin has the potential to induce and maintain remission in UC patients with no serious side effects. However, further studies with larger sample size are needed to recommend it as adjuvant therapy of ulcerative colitis.

References

Friedman S, Blumberg RS. Inflammatory bowel disease. In: Longo DL, Fauci AS, Kasper DL, Hauser SL, Jameson L, Loscalzo J, editors. Harrison’s principle of internal medicine. 18th ed. New York: McGraw-Hill. 2012. p. 1143-50.

Head KA, Jurenka JS. Inflammatory bowel disease part I: ulcerative colitis-pathophysiology and conventional and alternative treatment options. Altern Med Rev. 2003;8:247–83.

Xu C-T, Meng S-Y, Pan B-R. Drug therapy for ulcerative colitis. World J Gastroenterol. 2004;10:2311–7.

Allison MC, Dhillon AP, Lewis WG, et al. Inflammatory bowel disease. London: Mosby; 1998. p. 15–95.

Hanauer SB. Medical therapy of ulcerative colitis. Gastroenterol. 2004;126:1582–92.

Hanauer SB. Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities. Inflamm Bowel Dis. 2006;12:S3–S9.

Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet. 2007;369:1641–57.

Singla V, Mouli VP, Garg SK, et al. Induction with NCB-02 (curcumin) enema for mild-to-moderate distal ulcerative colitis – A randomized, placebo-controlled, pilot study. J Crohn’s Colitis. 2014;8:208-14.

Lang A, Salomon N, Wu JCY, et al. Curcumin in combination with 5-aminosalycilate induces remission in patients with mild to moderate ulcerative colitis in a randomized controlled trial. Clin Gastroenterol Hepatol. 2015;13(8):1444-9.

Hanai H, Iida T, Takeuchi K, et al. Curcumin maintenance therapy for ulcerative colitis: Randomized, multicenter, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol. 2006;4:1502-6.

Holt PR, Katz S, Kirshoff R. Curcumin therapy in inflammatory bowel disease: A pilot study. Digestive Dis Sci. 2005;50(11):2191-3.

Li Q, Jiang Q, Huang R, et al. Curcumin–piperine mixtures in self-microemulsifying drug delivery system for ulcerative colitis therapy. Int J Pharmaceut. 2015;490:22-31.

Xiao B, Si X, Zhang M, Merlin D. Oral administration of pH-sensitive curcumin-loaded microparticles for ulcerative colitis therapy. Colloids Surf B Biointerfaces. 2015;135:379-85.

Downloads

Published

2018-01-19

How to Cite

Simadibrata, M., Halimkesuma, C. C., & Suwita, B. M. (2018). Efficacy of Curcumin as Adjuvant Therapy to Induce or Maintain Remission in Ulcerative Colitis Patients: an Evidence-based Clinical Review. Acta Medica Indonesiana, 49(4), 363. Retrieved from https://actamedindones.org/index.php/ijim/article/view/520

Issue

Vol. 49 No. 4 (2017): Acta Medica Indonesiana

Section

SPECIAL ARTICLE

License

Copyright

The authors who publish in this journal agree to the following requirements:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a  Creative Commons Attribution 4.0 International License (CC BY 4.0) that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  2. Authors can enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) before and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work. (See The Effect of Open Access)

Privacy Statement

The names and email addresses entered in this journal site will be used exclusively for the stated purposes of this journal and will not be made available for any other purpose or to any other party.